Menu
Skip to content

High-intensity focused ultrasound (HIFU)

High-intensity focused ultrasound

The focus of the working group is the clinical use of therapeutic ultrasound, the innovative high-intensity focused ultrasound (HIFU), for treatment of various benign and malignant solid tumors. The main focus is on the HIFU treatment (1) of patients with inoperable pancreatic cancer for tumor mass reduction and relief of tumor-associated symptoms and (2) of patients with symptomatic uterine fibroids. The research group cooperates with international HIFU doctors from China, Spain, Bulgaria and Egypt.

HIFU-systems with ultrasound guidance

  • HIFU JC TTS, Chongqing, China
  • Theraclion Echopulse, France
  • Mirabilis, USA

Indications

  • Pancreatic cancer
  • Uterine fibroids, adenomyosis
  • Liver tumors (HCC, liver metastases)
  • Bone tumors
  • Breast tumors (fibroadenoma)
  • Rare tumors e.g. desmoid tumors
  • Thyroid nodes

Group Leader

PD Dr. med. Dr. rer. nat. Milka Marinova
E-Mail: Enable JavaScript to view protected content.

PD Dr. med. Claus C. Pieper
E-Mail: Enable JavaScript to view protected content.

Nurses

Frau Kathrin Bird
Frau Irene Zender
Tel.: +49 228-287 16464, 16413
E-Mail: Enable JavaScript to view protected content.

Unsere Webseite verwendet Cookies.

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

Unsere Webseite verwendet Cookies.

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

Your cookie preferences have been saved.

Information gemäß § 6 Medizinprodukte-Betreiberverordnung "Beauftragter für Medizinproduktesicherheit"

Sehr geehrte Damen und Herren,

gemäß § 6 Medizinprodukte-Betreiberverordnung steht Ihnen das Universitätsklinikum Bonn im Zusammenhang mit Meldungen über Risiken von Medizinprodukten, Informationen zu Rückrufen oder Warn- und Sicherheitshinweisen sowie bei der Umsetzung von notwendigen korrektiven Maßnahmen unter folgender E-Mailadresse zur Verfügung: Enable JavaScript to view protected content.

Diese E-Mailadresse richtet sich vorzugsweise an Kontaktpersonen von Behörden, Herstellern und Vertreibern von Medizinprodukten.